TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

Daily Photo Galleries

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Indian firm plans exports of ethane from U.S. shale fields
  2. Auto sales increase along with subprime loans
  3. UPMC earnings turn positive, but pressures mount
  4. EDMC to cut costs, roll out new grant
  5. GE could trade in appliance division
  6. Target cuts annual profit outlook
  7. Shared offices provide advantages for startups, nonprofits, others
  8. Sprint cancels Framily, rolls out new data pricing plan
  9. Energy sector powers Pa. pace
  10. Berkshire socked with $896K penalty
  11. Car lovers get special treatment
Subscribe today! Click here for our subscription offers.